de VakantieDiscounter wins two awards at the 2024 Website of the Year Awards

3I

The Website of the Year Awards are an annual online public vote for the most popular websites in the Netherlands.

de VakantieDiscounter won two awards at the 2024 Website of the Year Awards, including the most popular website of the year: 
  • Travel category: de VakantieDiscounter won this category for the third year in a row.
  • Overall most popular website: de VakantieDiscounter was voted the most popular website of the year across almost 40 categories.

de VakantieDiscounter attributes its awards to its efforts to improve its website based on customer feedback and to provide a great customer experience.

Categories: News

United Trust Bank Announces Minority Investment by Warburg Pincus

Warburg Pincus logo

United Trust Bank (UTB), a leading UK specialist bank, has announced that an agreement has been reached between its majority shareholders and Warburg Pincus, the pioneer of private equity global growth investing, whereby Warburg Pincus will acquire a minority equity interest in UTB.

This agreement, which is subject to the relevant regulatory approvals, will support the continuation of UTB’s strong growth and expansion into new products. The investment, which values the banking group at approximately £520 million, is a significant endorsement of UTB’s current strategy and future prospects.

UTB has been successfully building its business and brand for over 20 years with its focus on recruiting the best people, developing its product range and a disciplined approach to growth. Today, UTB has around 60,000 deposit customers and total assets approaching £4 billion. The Bank has dedicated divisions providing development finance, bridging finance, structured finance, asset finance, BTL finance and mortgages. UTB’s reputation for in-depth knowledge combined with commercial awareness and its robust funding model has made it a popular choice for finance brokers, developers and individuals seeking a high quality, bespoke service and a reliable source of finance solutions.

Harley Kagan, Chief Executive Officer of United Trust Bank, commented:

“This is an exciting milestone for UTB and an excellent opportunity for our staff, shareholders and for Warburg Pincus.

“I am delighted that Warburg Pincus will be joining us as a new partner to help accelerate our growth and provide support and experience as the group heads for a £4 billion balance sheet and explores exciting new products and markets in the future.

“It just remains for me to say that the growth story over the last 20 years would not have been achievable without the exceptional UTB staff who work carefully every day to build the Bank and deliver outstanding products and services to our customers, and for that we wish to sincerely thank them. United, we really do go further.”

Mike Thompson, Managing Director, Warburg Pincus, commented:

“We are delighted to partner with United Trust Bank as an investor and a strategic partner. UTB has established itself as a market leader in the UK, with an impressive track record of growth and innovation. The Bank’s strong management team, customer-centric approach, and focus on specialty lending solutions are key drivers of its success. We look forward to working closely with Harley and his team to support the Bank’s continued growth and leveraging the expertise of our Financial Services and Capital Solutions teams to help the company seize new opportunities in the UK market.”

Warburg Pincus was one of the first global private equity firms to invest in Europe in 1983, investing more than $15 billion in over 125 companies across more than 20 European countries. Within the financial services industry globally, Warburg Pincus has invested more than $25 billion across 60 companies, with a particular focus on specialist banking and lending. The firm has a successful track record of investing in capital solutions related transactions historically and recently closed the Warburg Pincus Capital Solutions Founders Fund, backed by over $4.0 billion in commitments.

UTB was advised by Lazard and CMS.

ENDS

Notes to editors:

For further information:

Jason Wyer-Smith – 42 PR: 07824 818242

To link to our website home page please use: http://www.utbank.co.uk/

United Trust Bank

UTB is an expanding specialist bank providing a wide range of secured funding facilities for individuals and businesses and deposit accounts for individuals, businesses and charities. UTB has been named ‘Specialist Bank of the Year’ four times at the Bridging and Commercial Awards and is the only lender to have done so.

UTB was incorporated in 1955. It is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. UTB is covered by the Financial Services Compensation Scheme and the Financial Ombudsman Service. The Bank is a member of UK Finance, a Patron of the National Association of Commercial Finance Brokers (NACFB), a Member of the Finance & Leasing Association (FLA), the Intermediary Mortgage Lenders Association (IMLA), a Member of the Bridging & Development Lenders Association (BDLA) and a Member of the Open Property Data Association (OPDA).

Warburg Pincus

Warburg Pincus LLC is the pioneer of private equity global growth investing. A private partnership since 1966, the firm has the flexibility and experience to focus on helping investors and management teams achieve enduring success across market cycles. Today, the firm has more than $86 billion in assets under management, and more than 230 companies in their active portfolio, diversified across stages, sectors, and geographies. Warburg Pincus has invested in more than 1,000 companies across its private equity, real estate, and capital solutions strategies.

The firm is headquartered in New York with offices in Amsterdam, Beijing, Berlin, Hong Kong, Houston, London, Luxembourg, Mumbai, Mauritius, San Francisco, São Paulo, Shanghai, and Singapore. For more information, please visit www.warburgpincus.com or follow us on LinkedIn.

Categories: News

Tags:

Rivean Capital has acquired a majority stake in Acture Group from IK Partners

IK Partners

Rivean Capital (“Rivean”) is pleased to announce that it has signed a definitive agreement to acquire a majority stake in Acture Group (“Acture” or “the Group”), a leading provider of holistic employee welfare solutions, from IK Partners (“IK”). The stake is being acquired from the IK Small Cap II (“IK SC II”) Fund, with Co-Founder and current CEO Maudie Derks, as well as the management team, reinvesting alongside Rivean.

Founded in 2008 and headquartered in Nijmegen, the Netherlands, Acture is a specialised outsourced service provider supporting corporates and staffing agencies in managing employee absence. The Group has an integrated approach to employee welfare, offering complementary services such as absence management and reduction, including case management and reintegration programmes, combined with an absence insurance proposition.

Acture’s heritage and longstanding experience as a pioneer in the private social security services market in the Netherlands have resulted in large amounts of valuable data being translated into innovative case management solutions supported by proprietary technology. With IK’s support since 2020, the Group completed four add-on acquisitions in the Netherlands and three in Germany, to further complement its proposition and expand its geographical footprint. Acture is also currently rolling out a mental health absence management platform, Evermood, in the Netherlands and the DACH region. Through its full-service offering, Acture is well positioned to fully unburden customers who are confronted with labour market shortages and rising absenteeism costs. At present, the Group employs approximately 390 full-time employees across its offices in the Netherlands and Germany.

Ready for the next phase of growth

The Group’s ambition to reinforce its position as a leading European provider of specialised outsourced services and insurance products requires further investment in the organisation to help develop its digital offering and platform capabilities. With Rivean’s support, Acture will continue along its international growth trajectory, accelerating the execution of its strategic growth plan and transforming from a leading Dutch player in the social security market, to a European total employee welfare platform.

Maudie Derks, CEO of Acture, said: “With the recent add-on acquisitions, Acture has taken its first steps into the international arena while simultaneously expanding its offering with a tech-driven wellbeing proposition. Through the new partnership with Rivean, we plan to accelerate our international roll-out, advance our ambitious growth trajectory and further develop the total employee welfare management concept. We would like to thank IK for their support over the past few years and look forward to joining forces with Rivean.”

Nikolai Pronk, Managing Partner at Rivean Capital, commented: “We are very impressed by Acture’s leading market position, supporting its customers with an integrated offering and with a track record of consistent growth. We look forward to partnering with Maudie and the management team to support Acture in its next development and international growth phase.”

Sander van Vreumingen, Partner at IK and Advisor to the IK SC II Fund, added: “Over the past four years, we have had the pleasure of working very closely with Maudie and her team. From the start, we have been impressed with the combined professionalism and expertise of the team, which has enabled both the successful implementation of multiple organic growth initiatives and execution of several bolt-on acquisitions. We are proud of all that we have achieved in partnership with Acture and would like to wish Maudie and her team all the very best in the next stage of their journey.”

Completion of the transaction is subject to obtaining merger clearance, AFM and works council approval.

For further questions, please contact:

Rivean Capital
Maikel Wieland
Partner – Head of Investor Relations & Co-Investments
Phone: +41 43 268 20 30
m.wieland@riveancapital.com

IK Partners
Vidya Verlkumar
Head of Communications and Marketing
Phone: +44 7787 558 193
vidya.verlkumar@ikpartners.com

About Rivean Capital

Rivean Capital (“Rivean”) is a leading European private equity investor for mid-market transactions,
active in the DACH region, the Benelux countries, and Italy. Funds advised by Rivean Capital manage
over EUR 5 billion in assets. Since its inception in 1982, Rivean has supported more than 250
companies in realizing their growth ambitions and has a strong track record of supporting and scaling
successful high-tech businesses with cross-border growth agendas, including footprint expansions and
operational excellence trajectories. Headquartered in Amsterdam, Netherlands, Rivean Capital also has
offices in Brussels, Frankfurt/Main, Milan, and Zug, enabling a strong local presence across key
European markets. For more information, visit riveancapital.com

Read More

About IK Partners

IK Partners (“IK”) is a European private equity firm focused on investments in the Benelux, DACH,
France, Nordics and the UK. Since 1989, IK has raised more than €17 billion of capital and invested in
over 195 European companies. IK supports companies with strong underlying potential, partnering with
management teams and investors to create robust, well-positioned businesses with excellent long-term
prospects. For more information, visit ikpartners.com

Categories: News

Tags:

Maven backs IP law firm with MEIF II debt funding

Maven

Lincoln-based intellectual property (IP) law firm, Panoramix, has secured a funding injection from the Maven managed Midlands Engine Investment Fund II (MEIF II) following support through the first Midlands Engine Investment Fund in 2022.

Published: Dec 12, 2024
Focus: MEIF Maven Debt Finance

Panoramix, a specialist IP law firm delivering high-quality and cost-effective legal services to both UK and overseas businesses, has secured a six figure follow on debt funding package through the Midlands Engine Investment Fund II via appointed Fund Manager for East and South East Midlands, Maven.

Today’s transaction follows Maven’s support through the first Midlands Engine Investment Fund in 2022, which played a critical role in enabling Panoramix to establish its presence in the East Midlands and expand its client base nationally while also growing its operations, building its team, and securing a permanent base in Lincoln.

Founded in 2019 by IP law specialist Kevin Hanson, Panoramix offers a flexible, attorney led service without the billable hours model commonly used across the industry. Instead, the business offers fixed fees based on task complexity and value, allowing clients to benefit from transparent and efficient services.

Panoramix supports a range of clients from start-ups and SMEs to multinational corporations across various sectors, including technology, healthcare, retail and manufacturing. It is also one of the few UK-based IP law firms authorised to conduct US trademark work, holding direct practice rights with the US Patent and Trademark Office, which enables it to provide UK clients with cost-effective US IP support.

The loan from the Midlands Engine Investment Fund II will provide Panoramix with the resources to implement a comprehensive marketing strategy aimed at expanding its client base, particularly in the US market, where it has already seen strong demand. The funding will also enable the company to recruit additional staff, including a client relationship manager, an administrative support role and a part-qualified patent attorney to support its growing operations.

Kevin-Hanson-Panoramix-Richard-Altoft-MavenRichard Altoft, Investment Director at Maven and Kevin Hanson, Founder of Panoramix.

“The support from Maven and the Midlands Engine Investment Fund I in 2022 was critical in enabling us to establish our business in the East Midlands and grow our client base nationally. With further funding through Midlands Engine Investment Fund II, we intend to double our headcount and turnover within the next 24 months. This will involve development of new service offerings and expansion into new international markets. The future is looking very bright as we continue to revolutionise the IP legal services industry.”

Kevin Hanson, Founder of Panoramix

“Panoramix has shown impressive growth through its innovative service model, establishing itself as a trusted provider of intellectual property services and is now well positioned to capitalise on sector opportunities. Our initial support through Midlands Engine Investment Fund I enabled the firm to expand its capabilities and build strong foundations for future growth. We are pleased to provide additional support with debt finance from Midlands Engine Investment Fund II to enable the business to continue to grow its team and expand to new markets.”

Richard Altoft, Investment Director at Maven

“This new round of funding from the Midlands Engine Investment Fund II follows investment from the first Midlands Engine Investment Fund, and we are pleased to see Panoramix continuing to thrive. This funding will support the company in creating new roles and exploring expansion opportunities overseas.”

David Tindall, Senior Investment Manager at British Business Bank

Through MEIF II – Debt Finance East and South East Midlands, Maven can provide flexible finance options to address a variety of business needs, including enhancing working capital, purchasing new machinery, capital expenditure, export finance, product development and team expansion. The Fund has supported a number of businesses across the region to date, including Advance Tapes, an independent adhesive tapes manufacturer, DUKE Distribution, a logistics and trackway installation provider, Vision4Sport, a sports hospitality specialist and sustainable tech business, Circulayo.

As Fund Manager of MEIF II – Debt Finance East and South East Midlands, Maven can provide business loans from £100,000 to £2 million to support both earlier and later stage businesses with real growth potential across a range of sectors. If your business, or the business you advise, is looking at debt finance as a solution to fund future growth please click here.

Categories: News

Tags:

SWIF Maven Equity Finance invests £750,000 in Tom Parker Creamery

Maven

The British Business Bank’s South West Investment Fund has marked its 100th deal in the region, delivering over £40 million of investment since its launch last year with a £750,000 investment from SWIF Maven Equity Finance into Tom Parker Creamery.

Published: Dec 12, 2024
Focus: SWIF Maven Equity Finance

Founded in 2018, Tom Parker Creamery is a producer of free-range milks and creams from British grass-fed herds. Based at Wincanton in South Somerset, the business produces natural, fully traceable, and sustainable dairy products. The range features free-range milk enriched with vitamins, naturally flavoured milks and cream, all sustainably produced and presented in nostalgic glass bottles.

The company serves several major retailers including Waitrose, Sainsbury’s, Tesco, and Ocado. It has also won various awards including a Great Taste Award (2024), The Farm Shop & Deli Best Product (2024), International Cheese & Dairy Awards; Best Health Drink (2021) and the Great British Food Awards (2022 and 2021).

Investment from SWIF Maven Equity Finance has supported the relocation to a larger facility, allowing for a significant increase in production capacity as the company continues to grow its customer base. The funding will also provide additional working capital, enable the business to increase its headcount and support further product development.

Tom Parker Creamery free ranged whole milk product

“We’re extremely excited to be working with Maven and the South West Investment Fund to help take our business to the second phase of our growth plan. With the current rise in awareness of ultra-processed foods, our range of award-winning products made with free-range British whole milk and natural ingredients mean we’re well positioned to satisfy consumer demands in this area. With this support, the investment enables us to deliver our ambitious plans and meet the rising demands from major retailers and consumers.”

Rob Yates, CEO of Tom Parker Creamery

“Tom Parker Creamery has carved out a unique space in the dairy market, driven by its commitment to high-quality, sustainably sourced products. Rob has built a strong brand, and we’re excited to back him and his team as they scale up and bring their exceptional products to more customers. The South West Investment Fund is there to support businesses just like this to grow whilst making a positive impact on the wider local economy.”

Rafi Khan, Investment Manager at Maven

“We’re thrilled to see the South West Investment Fund make its 100th deal, delivering over £40m of investment since its launch last year. The volume of investments underscores the strength and ambition of growing businesses across the South West, and the critical role of the fund in providing the capital needed for these businesses to innovate, expand, and create lasting impact in their communities. The latest investment in Tom Parker Creamery highlights our commitment to supporting sustainable, growth-oriented businesses in a broad range of sectors across the region.”

Jody Tableporter, Director UK & Regional Funds at the British Business Bank

The purpose of the South West Investment Fund is to drive sustainable economic growth by supporting innovation and creating local opportunity for new and growing businesses across the region. The Fund is increasing the supply and diversity of early stage finance for South West smaller businesses, providing funds to firms that might otherwise not receive investment and helping to break down barriers in access to finance.

SWIF – Maven Equity Finance can provide investment of up to £5 million to support ambitious earlier and later stage businesses across the South West of England. To date, the Fund has backed sustainable packaging innovator, Kelpi, global wireless solutions provider Blu Wireless, healthcare buy and build operator, Covestus, Microsoft adoption specialist, Changing Social and leading robotic additive manufacturer, Q5D.

Categories: News

Tags:

Why Platinum Equity Acquired ‘Proud’ Family-Owned Italian Pesto Sauce Producer Polli

Platinum

In 1872, Fausto Polli opened a small store front selling canned vegetables in the heart of Milan.

Since that humble beginning, the Polli family has grown the business to become a leading European producer of pesto and pasta sauces.

The company today operates four plants in which more than 130 different raw materials are processed, producing approximately 29,000 tons of vegetables and more than 190 million packages every year.

A core segment of the business is private label pesto where the company has a leading position in supplying products to European grocery store chains. Traditional pesto is made of basil leaves, pine nuts, garlic and olive oil – simple ingredients considered to be high in healthy fats and antioxidants.

With family eying further international expansion, Platinum Equity recently acquired a majority stake in the company. The Polli family retains a minority stake in the business together with CEO Marco Fraccaroli, who will continue to lead the company.

“Platinum has a lot of experience helping family-owned businesses leverage our M&A capabilities and global operating expertise to capitalize on market opportunities and maximize their potential,” Platinum Equity Co-President Louis Samson said in a released statement after the deal announcement.

“Polli has built an exceptional brand with a proud heritage, and we look forward to working together to build on that legacy.”

Manuela Polli, Managing Director of Polli and sixth generation family member, said: “We are excited to continue our ambitious journey with Platinum Equity, an important partner who shares our company’s values and goals. We are confident that together we will take the business to a new level of global leadership.”

The Polli investment was led by Platinum Equity’s European Small Cap investment team, which is experienced in acquiring businesses in the food and beverage sector.

Samson, Managing Director Fernando Goni and Senior Vice President Filippo Rossi recently gave their thoughts on one of Platinum Equity’s latest investments.

(Questions and answers have been edited for clarity)

Q: Describe the business.

Goni: Polli is a family-owned business that produces pesto sauces and other condiments. The business is mostly for private label, but they also have around 15% of the business which is branded Polli. They make many other products, but it’s mostly a pesto sauce business, selling primarily to large supermarket chains, so very strong in Europe. It’s a company that did extremely well in developing that pesto sauce market.

Samson: This was a family-owned asset for many generations and divesting it was a big decision. With two prior investments (Fantini Group and DeWave), we’re known in Italy and have a track record to stand on. The advisors knew us, and they contacted us on this deal 18 months ahead of it.

The family wasn’t sure initially they wanted to sell a majority share of the business, and it took a while for them to make that decision.

During that time, our team stayed close and developed a very good relationship with the family, especially with Manuela Polli, who’s really driving change and professionalizing the company. We have tremendous respect for the legacy they’ve built and I think over time the family realized that Platinum Equity would be a good home for the business and its next chapter. We have a shared vision to improve the business and grow outside of Italy in Europe and the United States and believe we can help.

Q: For the uninitiated, what is pesto sauce used for?

Goni: It is a very basic sauce that some make themselves or you can buy from the supermarket. It’s basically basil leaves, oil, pine nuts and cheese. It’s not a very complicated product. I live in the U.K. with my family, and we eat it a lot. When we started looking at Polli, I realized I had pesto sauce both in the fridge and in the cupboards.

Rossi: Italians eat it with pasta, but outside of Italy it is a lot more than a pasta sauce. You can mix it with salads and soups. You can put it in sandwiches. It goes on meat and fish as a topping. And it’s interesting that outside of Italy, pesto as a category is growing fast, mainly for its convenience and its flexible usage in vegetarian diets. And that was one of the reasons that we liked the upside potential on the deal.

Q: It’s another instance of Platinum Equity transacting with a family-owned company. Why does the Platinum Equity approach work when it comes to approaching family or founder-owned companies thinking of a possible exit?

Goni: With Polli, it may have been difficult to make a decision to sell because it’s an asset that has been in the family for a long time. I think aligning with the vision of the family is really important. When that alignment exists, I think what Platinum Equity can provide is operational expertise, resources and the ability to grow outside of these European markets. When that aligns with what the family is looking for, then you have a really good match.

Rossi: Every deal has its own history, and it is important to be flexible and provide a solution to the situation that we have in front of us.  With Polli, the family had successfully brought in professional management from the outside already, and performance had been outstanding with CEO Marco Fraccaroli driving the business from approximately € 90 to about € 200 million in revenues. Platinum Equity has helped the company through this generational transition, which is a sensitive topic in Europe.

Q: What will be the operational focus?

Goni: I think that there’s a path of creating more operational efficiencies. I think the other area where we can support them, and there is an opportunity, is on M&A. We’ll look at opportunities, source them, work with the team on executing those deals, integrating those companies. That’s going to be a major part of the deal going forward, and we can definitely team up with them and help on that.

Rossi: We see Polli as a great platform to continue investing in organic growth and also pursue acquisitions both in Europe and the U.S. There is an exciting ambition to establish a direct presence in new geographies or in adjacent fast-growing product categories like dips, snacks, ready-made meals.

Q: Why does Platinum like the food and beverage sector?

Samson:  We’ve made several investments in food and beverage, both in Europe and North America. We like the food and beverage space because it’s quite a stable market. We look at every segment and geography differently, but some of the fundamentals are the same. We really focus on the attributes, and then we see how we can improve the company that we’re buying. But effectively, it’s generally a stable market with typically good growth characteristics. And we like that.

Q: Tell us about Platinum’s strategy in Europe.

Samson: We’ve been in Europe for more than 20 years and we’ve really supercharged the effort in the last eight to ten years. We invested in human capital and infrastructure, and we built a team that has taken us to the degree of relevance and importance in the market that we’ve reached in North America. We didn’t build the team around American transplants into the European market, but instead addressed the European reality by having a multicultural group that understands local culture and speaks the languages, whether it’s Italian, French, Spanish, German, Portuguese, Dutch or English. We have also replicated our full suite of operational and carveout personnel and capabilities on the ground at the European level, which is a hallmark of Platinum’s approach and a big differentiator for us. So far, it’s paying off. We’ve been very active and we like our current position in the market.

 

Categories: News

Tags:

Intended Strategic Stake by VE Partners in Atrium Agri

VE Partners

Atrium Agri B.V., a leading player in high-tech greenhouse construction and technical installations for the global horticultural sector, today announces a proposed strategic partnership with Value Enhancement Partners (VE Partners). VE Partners intends to acquire a stake in Atrium Agri, enhancing the consortium’s focus on innovative solutions within Controlled Environment Agriculture (CEA). The proposed transaction has been submitted to the Dutch Authority for Consumers and Markets (ACM).

With a strong emphasis on sustainability and innovation, the consortium develops integrated solutions for greenhouse construction, automation, water management, and climate control. Atrium Agri operates globally with offices in Europe, China, Australia, North and Central America, and the Middle East.

The collaboration unites Atrium Agri’s impressive portfolio, including renowned brands such as Havecon, Bom Group, VB Group, CambridgeHOK, and Scre3ns for greenhouse construction, screening, and climate solutions, including geothermal energy; and PB tec for technical installations in water, energy, and internal logistics. This enables Atrium Agri to deliver turnkey, bespoke solutions across all continents.

With approximately 375 employees and revenue of €225 million in 2023, Atrium Agri holds a strong market position and the capability to play a leading role in the global transition to sustainable food production.

“This proposed partnership, with significant capital investment, offers us a unique opportunity to accelerate our international growth strategy, both organically and through acquisitions,” said Marck Hagen, CEO of Atrium Agri. “By combining VE Partners’ investment power and expertise with our innovative solutions and ambition, we strengthen our position as a global market leader and take a significant step toward a more sustainable future.”

The completion of this partnership is expected within the next month.

Categories: News

Tags:

Mayapada Healthcare Group Secures $157 Million Strategic Growth Investment from Bain Capital

BainCapital

Source: Mayapada Healthcare Group

Partnership Enables Mayapada Healthcare Group to Drive Innovation, Expand Reach, and Meet Indonesia’s Growing Healthcare Demand

Jakarta – December 12, 2024 – Mayapada Healthcare Group, a leading private premium healthcare provider specializing in multi-disciplinary and specialty care, announced a $157 million strategic growth investment from Bain Capital, a global private investment firm. It demonstrates strong confidence in Mayapada Hospital’s premium healthcare platform, which is well-positioned to meet the growing demand for high-quality care in Indonesia.

The investment be used to further scale access Mayapada Healthcare Group’s hospital platform through organic and strategic growth initiatives.  It will also support its mission to address Indonesia’s increasing demand for high-quality healthcare services, ultimately improving patient outcomes nationwide. This strategic partnership with Mayapada Healthcare Group aligns with Bain Capital’s global expertise in adding value to healthcare providers, including APMG, Estia Health, Grupo NotreDame Intermedica, HCA, and Nichii Gakken.

Founded in 2008, Mayapada Healthcare Group operates a growing network of premium hospitals to meet Indonesia’s increasing demand for high-quality healthcare. With seven hospitals across Indonesia, including a flagship hospital in Jakarta Selatan, the company serves a large part of the nation’s population and particularly in the densely populated island of Java. It prioritizes patient-centric care supported by advanced technology, specialized medical teams, and sustainable practices. Mayapada Healthcare Group has steadily expanded its footprint, adding five hospitals between 2018 and 2024, and currently has a substantial pipeline of brown and greenfield expansion. Committed to improving access to reliable healthcare, the organization continuously develops its facilities to address community needs, delivering safe, high-quality medical services to Indonesians.

“Indonesia faces a growing gap between healthcare supply and demand due to demographic shifts like an aging population and rising affluence,” said Jonathan Tahir, Chairman and Group CEO of Mayapada Healthcare Group. “Mayapada Healthcare Group is dedicated to making reliable, high-quality healthcare accessible to all Indonesians,” Tahir emphasized. “By leveraging technology and empowering our specialists, we aim to improve patient outcomes and set a new standard for innovative healthcare.”

“Bain Capital brings not just resources, but also deep expertise in helping healthcare providers thrive in a rapidly evolving ecosystem. We are excited for this partnership, which is rooted in a shared vision for what healthcare can achieve in Indonesia, ” Tahir concluded.

“Bain Capital is thrilled to partner with Mayapada Healthcare Group, whose mission and growth strategy align well with the evolving needs of Indonesia’s healthcare market,” said Sarit Chopra, Partner and Head of Special Situations, Asia at Bain Capital.  “As the private healthcare market in Indonesia is just beginning to develop, we have deep conviction that Mayapada has already built a strong foundation for continued growth. We’re committed to enhancing it with top talent, systems, and technology and we are eager to apply our global expertise to support Mayapada’s next growth phase.”

The investment was made through Bain Capital’s Special Situations strategy, which oversees over $20bn AUM and has invested $35bn since its inception.

The transaction is subject to regulatory and public shareholders approval, with targeted closing in early 2025.

###

About Bain Capital

Bain Capital, LP is one of the world’s leading private investment firms that creates lasting impact for our investors, teams, businesses, and the communities in which we live. Since our founding in 1984, we’ve applied our insight and experience to organically expand into numerous asset classes including private equity, credit, public equity, venture capital, real estate, life sciences, insurance, and other strategic areas of focus. The firm has offices on four continents, more than 1,850 employees, and approximately $185 billion in assets under management.  Bain Capital’s Special Situations strategy offers tailored capital solutions and strategic partnerships, meeting diverse needs across market cycles. With over $20 billion in assets under management, the team uniquely combines credit and equity expertise to deliver both financial and operational value beyond traditional providers. To learn more, visit (http://www.baincapital.com). Follow @BainCapital on LinkedIn and X (Twitter).

About Mayapada Healthcare Group
Mayapada Healthcare Group (PT Sejahteraraya Anugrahjaya Tbk.) (“SRAJ”) is a key business pillar of the Mayapada Group in the healthcare services sector. Mayapada Healthcare Group runs 7 (seven) hospitals with a total capacity of more than 1,000 beds, supported by more than 1,500 medical professionals who are experts in their fields. The seven hospitals of Mayapada Healthcare Group are Mayapada Hospital Tangerang, Mayapada Hospital Jakarta Selatan, Mayapada Hospital Bogor (BMC), Mayapada Hospital Kuningan, Mayapada Hospital Bandung and Mayapada Hospital Nusantara (IKN). Mayapada Hospital Jakarta Selatan obtained JCI accreditation in December 2024 while the other hospitals have the highest levels of accreditation domestically. Mayapada Healthcare Group operates several flagship services ‘Centers of Excellence’ including Tahir Neuroscience Center, Tahir Uronephrology Center, Cardiovascular Center, Gastrohepatology Center, Oncology Center, Orthopedic Center, Obstetrics & Gynecology Center, Pediatric Center, Internal Medicine and Pulmonology Center, Allergy-Immunology Center and the Autoimmune Center which is first and only service center in Indonesia. Mayapada Hospital Group has several projects in the pipeline and plans to operate more than 2,000 beds by 2027.

 Asia / China

 Zhen Trudy Wang

Categories: News

Tags:

Angitia Biopharmaceuticals Announces $120 Million Series C Financing

BainCapital

Source: Angitia Biopharmaceuticals

  • Financing led by Bain Capital Life Sciences with significant participation from existing and new investors
  • Proceeds will support the development of AGA2118, AGA2115, AGA111 and other pipeline assets for the treatment of serious musculoskeletal diseases
  • Norbert Riedel, Ph.D., will join the Board of Directors

WOODLAND HILLS, Calif. December 11, 2024 – Angitia Biopharmaceuticals (“Angitia” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, today announced the closing of a $120 million Series C financing round. Bain Capital Life Sciences led the financing, with participation from new investor Janus Henderson and existing investors OrbiMed, 3H Health Investment, Yonghua Capital, Legend Capital, and Elikon Venture. Proceeds from the Series C will support Angitia’s robust pipeline of novel, differentiated treatments for serious musculoskeletal diseases.

“The broad support for Angitia in this financing validates the hard work of our team, the clinical progress of our programs, and the quality of our emerging data,” said Dr. David Ke, M.D., Chief Executive Officer of Angitia. “We express gratitude to our investors, new and returning, for their support in our journey to provide novel and effective treatments for patients with musculoskeletal disease, and we look forward to continuing to execute on developing these valuable medicines.”

Angitia is advancing AGA2118 and AGA2115, bispecific antibodies targeting sclerostin and DKK1, through clinical development for osteoporosis and osteogenesis imperfecta (OI), respectively. The two molecules represent the next generation of dual-acting treatments for skeletal disease, increasing bone formation and decreasing bone resorption. With these two bispecifics, Angitia seeks to promote stronger, more organized skeletal development in patients. The Company is also developing AGA111, a biologic to promote spinal fusion in patients with degenerative disc disease.

In conjunction with the financing, Dr. Norbert Riedel, Ph.D., will join the Company’s Board of Directors. A seasoned scientist and biopharmaceutical executive, he brings decades of leadership experience to Angitia. Dr. Riedel serves on the board of directors of Jazz Pharmaceuticals and Eton Pharmaceuticals and is Chairman of the Board of Alcyone Therapeutics. He recently completed his tenure on the board of Cerevel Therapeutics. Dr. Riedel previously founded Aptinyx, Inc. and served as CEO of Naurex, which was acquired by Allergan in 2015. He also held senior roles at Baxter International and Hoechst-Marion Roussel (now Sanofi). Dr. Riedel holds a diploma in biochemistry and a Ph.D. in biochemistry from the University of Frankfurt.

Angitia is enrolling patients in a Phase 2 study in postmenopausal women with AGA2118 (NCT06577935). AGA2115 is being developed for the treatment of OI and is currently in a first-in-human study (NCT06086613). AGA111 is being explored for use in patients undergoing lumbar interbody fusion in a Phase 3 study (NCT06115512).

About Angitia Biopharmaceuticals

Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. Angitia is currently studying 3 biologic product candidates in the clinic for the treatment of osteoporosis, osteogenesis imperfecta (OI), and spinal fusion. Leveraging the team’s extensive experience and scientific acumen in novel drug development, Angitia is committed to providing groundbreaking therapies to satisfy key unmet medical needs.

Categories: News

Tags:

Gilde Healthcare Portfolio Company Noema Pharma extends Series B financing round

GIlde Healthcare
December 11, 2024
Basel (Switzerland)

Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced the successful close of a Series B extension financing round with an investment from EQT Life Sciences, bringing the total capital raised in the round to CHF 130 million (approx. USD 147 million). With its investment in Noema Pharma, EQT Life Sciences joins the syndicate of previous Series B investors including Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris Partners, Invus and UPMC Enterprises.

The new financing will support Noema Pharma’s four active Phase 2 trials, with key data readouts anticipated in 2025. This includes additional development activities for basimglurant (NOE-101), an mGluR5 negative allosteric modulator currently in Phase 2 trials for severe pain in trigeminal neuralgia (TN) and seizures in tuberous sclerosis complex (TSC); gemlapodect (NOE-105), a PDE10a inhibitor in a Phase 2b trial for Tourette syndrome and under development for childhood-onset fluency disorder (COFD or stuttering); and NOE-115, a broad-spectrum monoamine modulator in a Phase 2 trial for vasomotor symptoms and other symptoms of menopause.

Ilise Lombardo, MD, CEO of Noema Pharma, stated:”This latest financing underscores the strong support and confidence from investors in Noema’s vision to treat neuroscience-based conditions. We are thrilled to welcome EQT Life Sciences into this strong syndicate of investors and have Felice join our Board. EQT’s support and expertise alongside our syndicate of investors will be invaluable as we progress our clinical programs and strive to make a meaningful impact on patients’ lives.”

The Series B extension follows the initial Series B financing of CHF 103 million (USD 112 million) announced on March 2023, and a CHF 54 million (approx. USD 60 million) Series A round in December 2020.

About Noema Pharma
Noema Pharma is a clinical-stage biotech company advancing a portfolio of transformative, first-in-disease therapeutics targeting neuroscience-based conditions with high unmet need. Noema has four programs currently in active Phase 2 clinical trials evaluating seizures in Tuberous Sclerosis Complex, pain in Trigeminal Neuralgia, Tourette syndrome and vasomotor symptoms plus CNS-mediated symptoms of menopause with readouts expected in 2025. Noema was founded by leading venture capital firm Sofinnova Partners and is supported by current investors including Forbion, Gilde Healthcare, Invus, Jeito Capital, Polaris Partners and UPMC Enterprises. Learn more at www.noemapharma.com.

About Gilde Healthcare
Gilde Healthcare is a transatlantic specialist investment firm managing over €2.6 billion across two fund strategies: Venture&Growth and Private Equity. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in therapeutics, medtech and digital health, based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. For more information, visit the company’s website at www.gildehealthcare.com.

Categories: News

Tags: